Rare and orphan diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs
Blogs, Rare and orphan diseases
Is data drought holding back your orphan drug?
Thought Leadership, Rare and orphan diseases
Market access for orphan drugs in Switzerland: a guide for Biotechs
Blogs, Rare and orphan diseases
An introduction to PASS studies
Thought Leadership, Rare and orphan diseases
The impact of real-world data in gaining access to the European orphan drugs market.
Thought Leadership, Rare and orphan diseases
Navigating early access in Europe: a strategic blueprint for biotech leaders
Blogs, Rare and orphan diseases
Early access programs – benefits, challenges and the Sciensus solution
Thought Leadership, Rare and orphan diseases
Strategies for entering the European orphan drugs market
Thought Leadership, Rare and orphan diseases
Realize your European orphan drug expansion
Thought Leadership, Rare and orphan diseases
Take the risk out of your orphan drug distribution in Europe